Tissue engineering is an interdisciplinary field addressed to develop functional three-dimensional tissues combining cells, scaffolds, and bioactive molecules. This field involves scientific areas such as cell biology, chemistry, material science, molecular biology, medicine, and engineering. It can be used to develop functional constructs that can be used to reestablish, maintain or improve the condition of injured body parts or tissues. Tissue engineering also assist in regeneration of damaged tissues by combining cells from the body with highly porous scaffold biomaterials. Scaffold biomaterials act as templates for tissue regeneration and guide the growth of new tissue.
Global tissue engineering market is estimated to be valued at US$ 9,436.0 million in 2022 and is expected to exhibit a CAGR of 11.7% during the forecast period (2022-2030).
Figure 1. Global Tissue Engineering Market Share (%), by Material Type, 2022
Increasing prevalence of kidney related disorders is expected to drive growth of the tissue engineering market
Tissue engineering is gaining traction in various areas such as wound care, burn treatment, orthopedics, neurology, urological products, and others. Tissue engineering can play an important role in the management of pediatric patients. Tissue or organs absent at the time of birth, in congenital anomalies such as bladder exstrophy, esophageal atresia, and congenital diaphragmatic hernia pose a serious challenges in surgical repair. Moreover, tissue engineering approaches have become a significant area of interest in burn wound management. Tissue engineered skin substitutes have great potential for widespread applications in wound healing, particularly to address the limited availability of autologous skin increasing burn and trauma related injuries are expected to drive the global tissue engineering market growth. For instance, in Feb 2022, according to American Chemical Society, prevalence of chronic kidney disease (CKD) in the general population is estimated to be as high as 14% across the globe.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2021 | Market Size in 2022: | US$ 9,463.0 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2030 |
| Forecast Period 2022 to 2030 CAGR: | 11.7% | 2030 Value Projection: | US$ 22,908.1 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered : |
Acelity L.P. Inc., Allergan Plc., Athersys, Inc., B. Braun, BioMimetic Therapeutics, Bio Tissue Technologies, C. R. Bard, International Stem Cell, Integra Lifesciences, Medtronic, Inc., Organogenesis Inc., Osiris Therapeutics, RTI surgical, Inc., Stryker Corporation, Tissue Regenix Group Plc., and Zimmer Biomet. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2. Global Tissue Engineering Market Share (%), by Region, 2022
Increasing ageing population and chronic diseases on the rise, there is a need for more effective medical treatments and therefore a need for trained tissue engineering researchers are expected to drive market growth during the forecast period.
With an ageing population and chronic diseases on the rise, there is a need for more effective medical treatments and therefore a need for trained tissue engineering researchers to deliver these technologies. This is one of the major factor that is expected to drive the growth of the market. Tissue engineering offers alternatives to surgical reconstruction, transplantation, and directing mechanical devices to repair damaged tissues. For instance, in March 2020, according to National Library of Medicine, Spinal cord injury (SCI) affects an estimated three million persons worldwide, with ∼180,000 new cases reported each year leading to severe motor and sensory functional impairments that affect personal and social behaviors. As tissue engineering technology is being developed for use in a variety of different fields, particularly in the biomedical field, a clear understanding of the mechanisms of tissue engineering is important.
Global Tissue Engineering Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.
COVID-19 has affected the economy in three main ways: by directly affecting production and demand of drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, faced problems with regard to the transportation of drugs and vaccines from one place to another.
However, the COVID-19 pandemic had a positive impact on the global tissue engineering market, owing to increasing damages of organs due to COVID-19 and rising number of applications of tissue engineering as Tissue engineering (TE) strategies can be used to treat the damage with their interdisciplinary approaches. Tissue engineers could design drug delivery systems, scaffolds, and particularly biomaterials for the damaged tissues and organs. The key players in market were focused on developing and receiving approvals for new technologies such as 3D printing.
Global Tissue Engineering Market: Key Developments
In April 2022, Organogenesis Inc, a global leader in regenerative medicine, announced that the latest advanced wound care research on its PuraPly AM, Affinity, Apligraf, NuShield, Novachor, and Organogenesis Physician Solutions product lines would be showcased at the 2022 Symposium on Advanced Wound Care (SAWC) Spring Conference, held between April 6 and April 10, 2022, in Phoenix, Arizona.
In May 2021, 3D Systems, leading provider of 3D printing announced the acquisition of Allevi, Inc., is a technology company making 3 dimensional bioprinters and bioinks to expand regenerative medicine initiative by accelerating growth in medical and pharmaceutical research laboratories.
In May 2021, 3D Systems, leading provider of 3D printing announced the acquisition of German software firm, Additive Works GmbH to expand simulation capabilities for rapid optimization of industrial-scale 3D printing processes.
Global Tissue Engineering Market: Restraint
Currently available tissue engineering methods face several problems, including ineffective cell growth, insufficient and unstable production of growth factors to stimulate cell communication and proper response, and lack of appropriate biomaterials and techniques to capture appropriate physiological architectures. Furthermore, the inability to control cellular functions and their various properties (biological, mechanical, electrochemical, and others) and problems of biomolecular detection and biosensors are other limitations associated with tissue engineering.
Furthermore, despite the growing interest in tissue engineering research, progress and high cost associated with the treatment is hampering the growth of the market.
Key Players
Major players operating in the global tissue engineering market include Acelity L.P. Inc., Allergan Plc., Athersys, Inc., B. Braun, BioMimetic Therapeutics, Bio Tissue Technologies, C. R. Bard, International Stem Cell, Integra Lifesciences, Medtronic, Inc., Organogenesis Inc., Osiris Therapeutics, RTI surgical, Inc., Stryker Corporation, Tissue Regenix Group Plc., and Zimmer Biomet.
Tissue engineering is a scientific field majorly focused on the development of tissue and organ substitutes by controlling biophysical, biological, and/or biomechanical parameters in the laboratory. Tissue engineering has emerged as a rapidly expanding approach to address shortage of organs in transplantation procedures and is a major component of regenerative medicine. The general principles of tissue engineering involve combining living cells with a synthetic or natural support or scaffold to build a three dimensional living construct that is structurally, functionally, and mechanically equal to or better than the tissue that is to be replaced. The primary goal of tissue engineering is to activate the body's lost regenerative abilities and, if necessary, to replace damaged tissue with tissue implants. Due to the particular technical difficulties, the generation of tissue constructs requires particularly close collaboration by physicians, cell biologists, materials scientists and engineers. The main goal of tissue engineering is the development of functional substitutes for damaged tissue. It is estimated that the majority of tissue engineering products are used to treat injuries and congenital defects, while tissue engineering products are less commonly used to treat disease.
Market Dynamics
Increasing adoption of inorganic growth strategies by key players in market such as acquisitions is expected to drive market growth over the forecast period. For instance, in October 2021 3D Systems, an engineering company provides comprehensive products and services, including 3D printers, print materials, software, on-demand manufacturing services, announced the acquisition of Volumetric Biotechnologies, a Houston-based biotech company. Volumetric’s mission is to develop the ability to manufacture human organs using bioprinting methods. Through this acquisition, 3D Systems plans to establish a world-class research capability in Houston, Texas, related to life sciences.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients